A review--probable mechanism of action of curcumin for the treatment of Alzheimer disease (AD).
AD which is resulted from neuronal loss and atrophy particularly in temporo parietal andfrontal cortex with an inflammation response to the deposition of amyloid plaque and abnormal cluster of protein fragments and tangled bundles of fibres (neurofibrillary Tangles-NFT) and also increased presence of monocytes or macrophages in cerebral vessel wall and reactive or reactivated microglial cell in theparenchyma (1,2) along with decrease level of neurotransmitter (NT)-Acetylcholine
The present mainstay treatments for AD are:
1) Replacement of NT by increasing ACH(Acetylcholine) synthesis
2) Augmentation of the action of muscarinic and nicotinic receptor.
3) Reduction of synaptic ACH degradation with cholinesterase inhibitors (tacrine, donepezil, rivastigmine and, galantamine)
4) Removal of amyloid plague, NFT with anti-oxidant and anti-inflammatory agent (NSAIDS).
5) Prevention of metal toxicity Out of the above fivemainstays, thefeasibility of removing of amyloid plaque and the delaying effect on NFT formation may result in slowing of cognitive decline in the elderly.
The promising drug-Curcuminlonga (Turmeric), a Herb, taken as a food additive which is used extensively in the treatment of many medical condition is studied & evaluated for the treatment of Dementia and braininjuries including AD. Curcumin which is approved as an antioxidant, anti-inflammatory andantilipophilic agent improves the cognitive function of the patient suffering from AD.
MECHANISM OF ACTION: The three cholinesterase inhibitors- Rivastigmine, galantamine, donepezil which are approved by FDA, are used in US & Europe. They have the requisite affinity and hydrophobicity to cross the blood brain barrier and exhibit a prolonged duration of action, along with an excitatory amino acid transmitter mimic, memantine, constitute current modes of therapy; these are not disease modifying and have no well-documented actions on the pathology of Alzheimer's disease, however the bulk of the evidence indicates that they show the decline in cognitive function and behavioural manifestation for limited interval of time. Current clinical research efforts are directed to synergistic actions of arresting inflammatory process or neurodegeneration and combining cholinesterase inhibitor with selective cholinergic receptor modulation. (19)
The probable mechanism of action of curcumin as an anti-oxidant, antiinflammatory, also for delaying the degradation of neurons, metal chelation, and decreasing microglia transition is discussed in considering the findings and observations of the researchers and investigators.
It can act as afree radical scavenger and an anti-oxidant inhibiting lipid peroxidation and oxidative DNA damage. Curcumin as a potent inhibitor of cytochrome P450 can induce gluthathione-S-transferase& protect spatial memory impairment due to amyloid [beta] protein (4). It can diminished plaque burden and over all inflammation 5there by reducing the size of plaque and neurotic dystrophy in AD (6). It has possible effect on neurogenesis in hippocampus & increase level of brain derived neurotrophic factors (7,8,9)
Curcumin inhibits the suppression of oxidative damage, inflammation, cognitive disease amyloid accumulation (10) thereby decreasing progress of AD. Zhang (11) stated that Curcumin helps the macrophages to clear amyloid plaque indirectly through immune system. Further this agent when used for longer duration produces chronic activation of microglia cell which secretes cytokines and some reactive substances that exacerbate A -beta pathology. It has antiproliferative action on microglia by differentiating into a mature cell or undergoes apoptosis.It involves decreased astrocytes proliferation, improved myelogenesisand increased activity and differentiation of oligodendrocytes.
The inflammtory changes such as microgliosis, astrocytosis, & deposition of amyloid X2p[beta] peptide are decreased by curcumin (3,12). It inhibis Cox (2), phosholipases, transcription factor and enzyme involved in metabolising the membrane phospholipid into prostaglandins. It decreases the main chemical for inflammation and transcription of inflammatory cytokines and also a potent inhibitors of proinflammatorycytokinine production which are differ according to nature of target cells.It decreases lipid peroxidation and lipofuscin accumulation that is normally increased with age15 and increases the activity of superoxide dismutase and Na-K ATPase which is normally decrease with age. This agent protects cells from Beta A insult through antioxidant pathway (6) and elevation of total cellular glutathione level (6).
Curcumin is a potent inducer of hemoxygenase, a protein that provides sufficient cytoprotection by promoting the S-S inactivation of Nrf2. KeapI complex and increased binding to no-IARE thereby significant elevation of oxidised glutathione content (3,17,18) The level of [beta] amyloid in AD is decreased with curcumin which is more effective in low dose of longer duration than large dose of short duration (5) but at high dose it binds to [beta] amyloid and block itself. It increases phagocytosis of p amyloid which effectively clearing them from brain of patients with AD. (8)
DISCUSSION: As on 2008 numerous clinical trials (3) for various diseases like multiple myaloma, pancreatic and colon cancer, psoriasis etc are carried out by using Curcumin. Investigators like Shukala (1) and StixG (2) observed the anti-oxidant, antiamyloid and anti-inflammatory properties of curcumin.
Curcumin as an antioxidant inhibits LDLP (low density lipoprotein) oxidation and also free radical that deteriorate neurons associated with AD, Hurtington chorea,(HC), Parkinson disease (13). It improves neurological deficits, decreases mortality and reduces water content in brain (14) and also helps to ease symptoms of AD.
Curcumin by interaction with heavy metals- cadium, lead, prevent neurotoxicity caused by these metals through suppressing inflammatory damages by preventing metal induction of NF-Kappa. Amyloid plaque formation is increased by intracellular accumulation of cholestryl esters. Curcumin might exert beneficial effects on AD (12) by inhibiting cholesterol formation and decreasing serum peroxides as the formation of amyloid plaque due to intracellular accumulation of cholestryl ester is decreased
Further many UCLAResearchers observed that AD patients who stay indoor all the time and having Vit D deficiency, is having beneficial effect when treated with curcumin along with Vit [D.sub.3] as curcumin stimulate macrophages of immune system that clear the amyloid [beta]plaque. Curcumin enhances binding of [beta] amyloid macrophages and Vit D could strongly stimulate the uptake & absorption of [beta] amyloid in macrophages in most of the patients. (17)
Macrophage type (I) and Vit [D.sub.3]; and macrophage type (ii) and Curcumin though they perform different function independently, must allow to work together for removal of amyloid protein effectively in the brain. Most people need to supplement with 5000-7000 units of Vit [D.sub.3] per day or rely on sun exposure to obtain the ideal level. Adding of curcumin to the diet 300-500 mg per day will provide a synergistic effect to clear brain tangles and prevent Alzheimer's dementia. (18)
Any person with significant cognitive decline due to inefficient Trash removal will have to use Vit D which actually turns on the genes within macrophages to rejuvenate the Trash removal ability. It certainly would not hurt to add some curcuminto the brain rejuvenation program. Vit [D.sub.3] and curcuminoid activate the opening of chloride channel which supports the uptake of amyloid beta in macrophages type one. (18)
Diet supplements--vegetables/foods containing antioxidants like vitamin C and E when taken/given together with curcumin improve the cognitive capability/memory of the elderly as the activity of curcumin for removal of amyloid beta plaque may be potentiated or slowing down the function of NFT or delayed the accumulation of Trash in the brain.
Thus, from the above probable mode of action of Curcumin extract, if purified may be very essential for delaying the progress of AD as well as for use as cognitive enhancer. But, further investigation and detailed studies will reap a great dividend in future for the treatment of Alzheimer disease associated with cognitive defects particularly for the geriatric patient.
1. Shukla, PK. Khanna, V.K.; Ali, M. M; Khan, M.Y; Srimal, R.C; "Anti-ischemic effect of Curcumin in Rat Brain" Neurochemical (2008) 33(6)1036-1043.
2. Stix.G "SpiceHealer' Scientific American, (Feb 2007) http://Sciam.com/article.efm7chan
3. Ringman JM, Frautschy SA, Cole GM, et al: A potential role of the curry spice Curcumin in Alzheimer disease: CURR ALZHEIMER Rech.2005, April, 2(2):131-6
4. Shukla, P.K.; Khanna, V.K.; Khan, M.Y.; Srimal, R.C.; "Protective effect of curcumin against lead neurotoxicity in rat:. Human & Experimental Toxicology, (2003) 22(12):653-658.
5. Frautschy, S.A.; Hu, W.; Kimm P.; Millerm S.A.; Chu, T.; Harris-white, M.E.; Cole, G.M. "Phenolic anti-inflammatory antioxidant reversal of Ap-induced cognitive deficits and neuropathology". Neurobiology of Aging, (2001) 22(6):993-1005.
6. Lim, G.P; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole G.M. "The curry spice Curcumin reduces oxidative damage and amyloid pathology in an AlZheimer transgenic Mouse"(pdf). Journal of Neuroscience (2001)21(21):8370-8377.
7. Xu, Y.; Ku, B.; Cui, L.; Li, X.; Barish, P.A.; Foster, T.C.; Ogle, W.O. "Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats". Brain Research (2007), 1162:9-18.
8. Wu, A.; Ying, Z.; Gomez-Pinilla, F. "Dietary curcumin counteracts the outcome of traumatic brain injury of oxidative stress, synaptic plasticity, and cognition" Experimental Neurology, (2006). 197 (2): 309-317.
9. Bala, K.; Tripathy, B.C.; Sharma, D. "Neuroprotective and anti-ageing effects of Curcumin in aged rat brain regions". Biogerontology. (2006) 7 (2):81-89.
10. Ng TP, Chiam PC, Lee T, Chau HC, LimL, Kau EH: Curry consumption and cognitive function in the elderly: Am. J. Epideuol.2006 No.1; 164(9):898-906.
11. Zhang L, Fiala M, Cashman J, Sayre J, Espinosa A, Mahanian M, et al. Curcuminnoids enhance amyloid-beta uptake by macrophages of Alzheimer disease patients.: J. Alzheimer Disease 2006; 10:1-7
12. Soni KB, Kuttan R, Effect of oral Curcumin administration on serum peroxides and Cholesterol in Human Volunteers. Indian J. Physiol Pharma.1992.36.273-5
13. Rasyid A, Rahman AR, Jaalam K, Laleo A: Effect of different curcumin dosages on human Gall bladder Asia Pac.J.Clin Nutr.2002; 11,314-8
14. (a) ShrikantMishra, KalpanaPalanivelu: The effect of curcumin (turmeric) on Alzheimer's disease: An overview-Annal of Indian Academy of Neurology:2008,11(1)13-19 (b) ShirshirShishoda, GautamSethi, & Bharat B. Aggrawal: Curcumin: Getting back to the Roots::Ann N.Y.A cad.Sci. (2005)1056:206-217
15. Youssef KM, El Sherbeny MA: Synthesis and antitumor activity of some curcuminanalogs. Arch Pham (Weinhein) 2005.338, 181-9.
16. Geol, A.;Kunnumakkara, A.B; Aggrawal, B.B. "Curcumin as 'Curcumin': from Kitchen to clinic 'Biochemical Pharmacology/2008/ 75(4):787-809.
17. Masoumi. A; Goldenson. B, Ghirmai. S, Avagyan.H, Zaghi. J, Abel. K, Zheng. X, Erpiuson, Jeffry. A, Mahanian. M, Liu. P.T. Alwison. M, Mizwick .I.M; Cashman. J, Fialas. M, "1 & 25 Dihydroxy vitamin D(3)interact curcuminoids to stimulate Amyloid-p clearance by Macrophages of Alzheimer's disease patient". Journal of Alzhiemer's disease, 2009, vol.17.No.3 page.703-717.
18. Bartik. L, Whitefield. GK, Kaczmarska. M, Low Miller.C.L, MoffetE.W;Furmick. J.K, Hernandez. Z, Haussler. C.A; Haussler.M.R, Jurut.K.PW; "Curcumin: A novel nutritionally derived ligand of the vitamin D receptor with implication for colon cancer Chemoprevention" J. Nutri. Bidchem. 2010.Dec, 21(12):115-61
19. P Taylor: Anticholinesterase agents; Goodman and Gilman's The pharmacological basis of therapeutics. McGraw Hill, 12th Ed; 2011; 239-254.
O. Joychandra, Varkung Valte
[1.] Assistant Professor, Department of Pharmacology, J. N. Institute of Medical Sciences, Imphal.
[2.] Assistant Professor, Department of Pharmacology, J. N. Institute of Medical Sciences, Imphal.
Dr. O. Joychandra, J. N. Institute of Medical Sciences, Imphal, Manipur, E-mail: email@example.com
Ph: 0091 9436030274.
|Printer friendly Cite/link Email Feedback|
|Author:||Joychandra, O.; Valte, Varkung|
|Publication:||Journal of Evolution of Medical and Dental Sciences|
|Date:||Jan 14, 2013|
|Previous Article:||Prevalence of iron deficiency among school going adolescent females in rural area of Wardha district of Maharashtra.|
|Next Article:||Pulmonary pseudallescheriasis in an immunocompetent patient--a case report.|